METHODS OF TREATING UROLOGICAL DISORDERS USING SARMs

A method of reducing the occurrence or lessening the severity of at least one of the following symptoms in a subject suffering from urinary incontinence:

• (i) average daily frequency of urination;
• (ii) average nightly frequency of urination;
• (iii) total urinary incontinence episodes;
• (iv) stress incontinence episodes;
• and (v) urinary urgency episodes;
• comprising administering a SARM compound of Formula IA:
• wherein
• R2 is H, F, Cl, Br, I, CH3, CF3, OH, CN, NO2, NHCOCH3, NHCOCF3, NHCOR, alkyl, arylalkyl, OR, NH2, NHR, N(R)2, or SR;
• R3 is H, F, Cl, Br, I, CN, NO2, COR, COOH, CONHR, CF3, Sn(R)3, or R3 together with the benzene ring to which it is attached forms a fused ring system represented by the structure:
• R is alkyl, haloalkyl, dihaloalkyl, trihaloalkyl, CH2F, CHF2, CF3, CF2CF3, aryl, phenyl, halogen, alkenyl or OH;
• Z is NO2, CN, COR, COOH, or CONHR;
• Y is CF3, F, Br, Cl, I, CN, or Sn(R)3;
• Q is CN, alkyl, halogen, N(R)2, NHCOCH3, NHCOCF3, NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH3, NHCSCF3, NHCSR, NHSO2CH3, NHSO2R, OR, COR, OCOR, OSO2R, SO2R or SR;
• or Q together with the benzene ring to which it is attached is a fused ring system represented by structure A, B or C:
• n is an integer of 1-4;
• and
• m is an integer of 1-3;
• or its optical isomer, pharmaceutically acceptable salt, hydrate, or any combination thereof.

A method of treating, preventing, suppressing or inhibiting pelvic floor disorders in a subject, comprising administering a SARM compound of Formula IA:

• wherein
• R2 is H, F, Cl, Br, I, CH3, CF3, OH, CN, NO2, NHCOCH3, NHCOCF3, NHCOR, alkyl, arylalkyl, OR, NH2, NHR, N(R)2, or SR;
• R3 is H, F, Cl, Br, I, CN, NO2, COR, COOH, CONHR, CF3, Sn(R)3, or R3 together with the benzene ring to which it is attached forms a fused ring system represented by the structure:
• R is alkyl, haloalkyl, dihaloalkyl, trihaloalkyl, CH2F, CHF2, CF3, CF2CF3, aryl, phenyl, halogen, alkenyl or OH;
• Z is NO2, CN, COR, COOH, or CONHR;
• Y is CF3, F, Br, Cl, I, CN, or Sn(R)3;
• Q is CN, alkyl, halogen, N(R)2, NHCOCH3, NHCOCF3, NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH3, NHCSCF3, NHCSR, NHSO2CH3, NHSO2R, OR, COR, OCOR, OSO2R, SO2R or SR;
• or Q together with the benzene ring to which it is attached is a fused ring system represented by structure A, B or C:
• n is an integer of 1-4;
• and
• m is an integer of 1-3;
• or its optical isomer, pharmaceutically acceptable salt, hydrate, or any combination thereof.

A method of treating, preventing, suppressing or inhibiting an urinary incontinence in post-hysterectomy or post-oophorectomy women, comprising administering a SARM compound of Formula IA:

• wherein
• R2 is H, F, Cl, Br, I, CH3, CF3, OH, CN, NO2, NHCOCH3, NHCOCF3, NHCOR, alkyl, arylalkyl, OR, NH2, NHR, N(R)2, or SR;
• R3 is H, F, Cl, Br, I, CN, NO2, COR, COOH, CONHR, CF3, Sn(R)3, or R3 together with the benzene ring to which it is attached forms a fused ring system represented by the structure:
• R is alkyl, haloalkyl, dihaloalkyl, trihaloalkyl, CH2F, CHF2, CF3, CF2CF3, aryl, phenyl, halogen, alkenyl or OH;
• Z is NO2, CN, COR, COOH, or CONHR;
• Y is CF3, F, Br, Cl, I, CN, or Sn(R)3;
• Q is CN, alkyl, halogen, N(R)2, NHCOCH3, NHCOCF3, NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH3, NHCSCF3, NHCSR, NHSO2CH3, NHSO2R, OR, COR, OCOR, OSO2R, SO2R or SR;
• or Q together with the benzene ring to which it is attached is a fused ring system represented by structure A, B or C:
• n is an integer of 1-4;
• and
• m is an integer of 1-3;
• or its optical isomer, pharmaceutically acceptable salt, hydrate, or any combination thereof.

A method of increasing the size and/or weight of muscles in the pelvic floor of a subject, comprising administering a SARM compound of Formula IA:

• wherein
• R2 is H, F, Cl, Br, I, CH3, CF3, OH, CN, NO2, NHCOCH3, NHCOCF3, NHCOR, alkyl, arylalkyl, OR, NH2, NHR, N(R)2, or SR;
• R3 is H, F, Cl, Br, I, CN, NO2, COR, COOH, CONHR, CF3, Sn(R)3, or R3 together with the benzene ring to which it is attached forms a fused ring system represented by the structure:
• R is alkyl, haloalkyl, dihaloalkyl, trihaloalkyl, CH2F, CHF2, CF3, CF2CF3, aryl, phenyl, halogen, alkenyl or OH;
• Z is NO2, CN, COR, COOH, or CONHR;
• Y is CF3, F, Br, Cl, I, CN, or Sn(R)3;
• Q is CN, alkyl, halogen, N(R)2, NHCOCH3, NHCOCF3, NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH3, NHCSCF3, NHCSR, NHSO2CH3, NHSO2R, OR, COR, OCOR, OSO2R, SO2R or SR;
• or Q together with the benzene ring to which it is attached is a fused ring system represented by structure A, B or C:
• n is an integer of 1-4;
• and
• m is an integer of 1-3;
• or its optical isomer, pharmaceutically acceptable salt, hydrate, or any combination thereof.

A method of increasing the size and/or weight of urethral sphincter of a subject, comprising administering a SARM compound of Formula IA:

• wherein
• R2 is H, F, Cl, Br, I, CH3, CF3, OH, CN, NO2, NHCOCH3, NHCOCF3, NHCOR, alkyl, arylalkyl, OR, NH2, NHR, N(R)2, or SR;
• R3 is H, F, Cl, Br, I, CN, NO2, COR, COOH, CONHR, CF3, Sn(R)3, or R3 together with the benzene ring to which it is attached forms a fused ring system represented by the structure:
• R is alkyl, haloalkyl, dihaloalkyl, trihaloalkyl, CH2F, CHF2, CF3, CF2CF3, aryl, phenyl, halogen, alkenyl or OH;
• Z is NO2, CN, COR, COOH, or CONHR;
• Y is CF3, F, Br, Cl, I, CN, or Sn(R)3;
• Q is CN, alkyl, halogen, N(R)2, NHCOCH3, NHCOCF3, NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH3, NHCSCF3, NHCSR, NHSO2CH3, NHSO2R, OR, COR, OCOR, OSO2R, SO2R or SR;
• or Q together with the benzene ring to which it is attached is a fused ring system represented by structure A, B or C:
• n is an integer of 1-4;
• and
• m is an integer of 1-3;
• or its optical isomer, pharmaceutically acceptable salt, hydrate, or any combination thereof.